The CMO and colleagues from the Department of Health had a meeting. The NHS Executive Board had not yet come to a firm view on funding of interferon treatment, and a cautious approach was necessary.
Chronology Information
Date:
Chapter/issue
Access to Treatment
Key Person(s)
Dr Graham Winyard